Phaseline

Companies › Neurotronic

Neurotronic: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Neurotronic Catheter–Phase 1Diabetes Mellitus, Type 2Jan 2029
Single Arm non-Randomized Ablation Treatment–Phase 1Diabetes Mellitus, Type 2Jan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05369065Single Arm non-Randomized Ablation TreatmentPhase 1Diabetes Mellitus, Type 2CardiovascularJan 2029
NCT05363761Neurotronic CatheterPhase 1Diabetes Mellitus, Type 2CardiovascularJan 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.